Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a ...

Eupraxia's EP-104GI is currently in a Phase 1b/2a trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of ...

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...

That can damage the cells lining the esophagus, prompting them to grow back with genetic mistakes.About 22,370 times a year in the United States, those mistakes culminate in cancer.Esophageal cancer ...

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with significant unmet need, ...

which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis ("EoE"). New Clinical Data from the Fourth Cohort of the RESOLVE Trial The results announced ...

Steroid injection combined with oral steroid therapy outperformed other steroid administrations for preventing esophageal stricture post-ESD.